Shares mag. recommending this stock this week. Is this going to be our killer this christmas!!!! any comments anyone?????

Let's hope so - it's been a long time coming!

Cenes 26th May 2006 Research Report available at the site below :

http://www.objectivecapital.co.uk/

http://www.proactiveinvestors.com/

Just found this article.Very promising indeed.
The site is free to register on and to read the article.Useful site for those that have not seen it.

CeNes: Future looks bright.
By William Foss.

Restructuring a publicly listed company is a painstaking and tedious operation. Over the past three years, CeNes, a pharmaceutical junior, has been the subject of an intense restructuring program to get the company refocused on drug discovery. Cenes went under the knife in an attempt to streamline it's pipeline and build up a cash reserve.

Thanks h.hairettin.

Good news from CeNeS, particularly the bit about potential revenue stream. I notice someone jumped in yesterday with a late reported trade this morning. Must be nice to have inside information.

pth

CeNeS Pharmaceuticals PLC
13 June 2006


Data on CeNeS short-acting sedative to be presented at at the American Society
for Anesthesiology meeting, 2006.


Cambridge, UK, 13th June 2006 - CeNeS Pharmaceuticals plc (AIM: CEN) ('CeNeS' or
'the Company') today announced that four abstracts highlighting the profile of
the short-acting sedative, CNS 7056X, have been accepted for presentation at the
American Society for Anesthesiology (ASA) meeting to be held in Chicago on
14-18th October 2006. One of the abstracts has been selected as a high profile
platform presentation.

The data to be presented at the ASA meeting will highlight the very encouraging
pre-clinical profile of CNS 7056X, including new results showing a rapid onset
and offset of sedative action and rapid metabolism by human liver samples. The
compound is being developed primarily as a sedative for short non-surgical and
surgical procedures. In addition, on the basis of these new data, CeNeS is now
evaluating the potential of CNS 7056X for use in the induction and maintenance
of anaesthesia. Pre-clinical studies to evaluate the potential of CNS 7056X in
these additional indications are being undertaken at The University of
Strasbourg, The University of Adelaide and under a Material Transfer Agreement
at a major pharmaceutical company. The evaluation will complete in the second
half of 2006. Extending the development of CNS 7056X to include the induction
and maintenance of anaesthesia could double the estimated potential market
opportunity to over 400m.

CNS 7056X is the lead compound of a series that was assigned to CeNeS from
GlaxoSmithKline in November 2003. Pre-clinical development work is ongoing with
the intention of filing an IND in the U.S. in 2006. Thereafter, CeNeS is
planning to conduct the first proof of concept Phase I study in the U.S., a
major potential market for short acting sedatives.


Neil Clark, Chief Executive, commented: 'The American Society for Anesthesiology
meeting is the largest gathering of anaesthesiologists in the world with up to
18,000 attendees expected. We are delighted to see that data on our short-acting
sedative will be presented at such an important conference. We are also very
excited by the potential of CNS 7056X for the additional indications of
induction and maintenance of anaesthesia. Presenting at this conference will
enable to us to access key opinion leaders and potential global partners of CNS
7056X'

CeNeS. Phase III study of M6G is to go head to head with morphine.. The study will be made double blind in a way that carer nor patient will be aware of which treatment is being given.. Six Euro countries will be involved, giving a total of twenty sites

CeNeS is out to prove that their M6G drug works faster, giving a lower levels of nausea and a fair comparison of pain management. The study will allow patients to self administer a dose of M6G..

In a nutshell CeNeS is after the sales of M6G for post operative pain.. The market could reach 200m PA.. The next stage as I see it is to secure the valuable licensing agreement.. with partners who are able to offer strong marketing off this major drug to be

The interim results are out visit CeNeS website Over the next few months there should be a steady flow of news Any one out there in on this one

I am myway. Have been holding for some time now and frustrated by the lack of newsflow. If that's about to change so much the better. Seems they're pretty confident of M6G......

Hi queen... as far as I see it M6G is the key to the next stage of CEN SP movment.. I feel that so many companies let them selves down through lack of news flow...

Indeed....as long as it's good news flow!!

The proof of the pudding take time out and read the CeNeS PH Plc write-up in last weeks Investors Chronicle M6G the new pain relief drug to-be.. Is now working through its phase III trials.. Look out for data on the trials by the year end or early 2007.

The company is running short of cash, however the late stage trials for M6G and phase II trials for diabetic neuropathic pain drug CNS5161 should come good.. For cash flow as potential partners are keeping their eyes on the trials

Just what are we looking here a possible replacement for morphine.. I will say no more..

I might need some of either product unless something happens positively after all this :-)

There has been a fair amount of trading of CEN shares over the last week.. Today I found out that UBS AG now hold a total of 16,341,340 or 3.66% of the companies issued share capital.. Which is indeed first class news for the private investors.. As a matter of interest UBS has taken profit on some of the position.. However they are still holding 3.66% of the total issue..

An announcement released by London Asia Chinese Private Equity Fund 17th of October 2006 concerning a 2.1 million investment in China Solar, a Chinese solar thermal business.

China Solars core business is the design and manufacture of solar energy buildings in China, based on its patented solar thermal technology.

Simon Littlewood, Executive Director of LACPEF, commented: The Company has patented technology, an experienced management team, a strong research and development programme, and strong support from the Chinese Government. There are significant opportunities for the Company to expand rapidly to take advantage of its strong brand and first-mover advantage, and the increasing emphasis by the Chinese Government on renewable energy sources and improving the quality of life for the poor.

This is yet another investment by LACPEF.. In China from the private equity fund Investors in London Asia should feel the benefit of this investment I am now looking forward to the results of yesterdays meeting in London with LACPEF and representative of the PLUS markets.. Institutional investors, private investors, brokers and the financial presskeep your eyes open..

LDC togther with LACPEF is moving in the right direction visit www.shareclubuk.co.uk to find out all the news flow for the last six months.. To my mind the LDC business is building up along the right line's ... Keep your eyes open on this one...

What will come first, good results and partnership or a fund-raising at discount?

Cen has made the move to appoint JM Finn & Co Ltd., as its joint broker The company is making way for the markets reaction to Phases III results due out end of year for M6G morphine-6-glucuronide as we all are..

Nice little speculative play write-up in Shares Mag this week.

Been away so placed an order earlier this week.
Just checked and looking good, up already.
Got a feeling when the M6G phase III results are out this will fly.

18,218,723 CeNeS shares traded last week to take the SP up to 6.25p All the AOPs at shareclubuk have were full of activity trying to find out why the SP has been going up we know that the phase III M6G study is on-going.. But we can-not find anyother reason why the SP is trading so well.. Any one out there who can give a reason why..?

Will M6G act as a replacement for morphine thats what Peter our 79 year old was saying at this mornings coffee meeting at the OAPs shareclubuk if so then we should be in clover he then when on to say that at the moment we are trading in the red to the tune of just under 500 on our investment with CeNeS.. Just the same as everyone else we are sitting on our hands waiting the results from the M6G trial.. Then we trust that we can turn the loss into profit..

Peter has Parkinsons said he would like also to see some movement on CeNeS COMT inhibitors - Parkinsons Any one has any news as to a possible partner for M6G?

Hi, does anyone have any idea as to the sudden activity here?

No news afa I know so why has the sp jumped after a lot of months of total inactivity and for no apparent reason plus a lot of buys going through.